28 related articles for article (PubMed ID: 34425405)
1. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system.
Crumley AB; Stuart RC; McKernan M; Going JJ; Shearer CJ; McMillan DC
J Gastrointest Surg; 2010 May; 14(5):781-7. PubMed ID: 20148314
[TBL] [Abstract][Full Text] [Related]
2. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study.
Busby J; Karasneh R; Murchie P; McMenamin Ú; Gadalla SM; Camargo MC; Iversen L; Lee AJ; Spence AD; Cardwell CR
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):48-56. PubMed ID: 31713940
[TBL] [Abstract][Full Text] [Related]
3. The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study.
Dalhammar K; Malmström M; Schelin M; Falkenback D; Kristensson J
PLoS One; 2020; 15(6):e0235045. PubMed ID: 32569329
[TBL] [Abstract][Full Text] [Related]
4. Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome.
Puhr HC; Pablik E; Berghoff AS; Jomrich G; Schoppmann SF; Preusser M; Ilhan-Mutlu A
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188713
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
Purim O; Beny A; Inbar M; Shulman K; Brenner B; Dudnik E; Bokstein F; Temper M; Limon D; Matceyevsky D; Sarid D; Segal A; Semenisty V; Brenner R; Peretz T; Idelevich E; Pelles-Avraham S; Meirovitz A; Figer A; Russell K; Voss A; Dvir A; Soussan-Gutman L; Hubert A
Target Oncol; 2018 Apr; 13(2):217-226. PubMed ID: 29353436
[TBL] [Abstract][Full Text] [Related]
6. Assessing real-world representativeness of prospective registry cohorts in oncology: insights from patients with esophagogastric cancer.
Kuijper SC; Besseling J; Klausch T; Slingerland M; van der Zijden CJ; Kouwenhoven EA; Beerepoot LV; Mohammad NH; Klarenbeek BR; Verhoeven RHA; van Laarhoven HWM
J Clin Epidemiol; 2023 Dec; 164():65-75. PubMed ID: 37871837
[TBL] [Abstract][Full Text] [Related]
7. Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases.
Revés J; Torres J
J Crohns Colitis; 2024 Jan; ():. PubMed ID: 38233095
[No Abstract] [Full Text] [Related]
8. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Takahashi Y; Sunakawa Y; Inoue E; Kawabata R; Ishiguro A; Kito Y; Akamaru Y; Takahashi M; Yabusaki H; Matsuyama J; Makiyama A; Tsuda M; Suzuki T; Yasui H; Matoba R; Kawakami H; Nakajima TE; Muro K; Ichikawa W; Fujii M
Gastric Cancer; 2022 Jan; 25(1):235-244. PubMed ID: 34427838
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
[TBL] [Abstract][Full Text] [Related]
11. Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.
Alsina M; Tabernero J; Diez M
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326560
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
[TBL] [Abstract][Full Text] [Related]
13. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
14. Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
Haj Mohammad N; Bernards N; van Putten M; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2017 Jun; 78():28-36. PubMed ID: 28412586
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of patient reported outcomes in advanced gastro-oesophageal cancer: a systematic review.
Naher SK; Mercieca-Bebber R; Siu D; Grimison P; Stockler MR
Intern Med J; 2023 Nov; 53(11):1946-1955. PubMed ID: 37605848
[TBL] [Abstract][Full Text] [Related]
17. The association between effectiveness of first-line treatment and second-line treatment in gastro-oesophageal cancer.
van Velzen MJM; Pape M; Dijksterhuis WPM; Slingerland M; van Voorthuizen T; Beerepoot LV; Creemers GJ; Derks S; Mohammad NH; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2021 Oct; 156():60-69. PubMed ID: 34425405
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
